Shows
Health CheckStatins rarely cause muscle painStatins save lives by lowering the level of 'bad' cholesterol in our blood, reducing the risk of heart attacks and strokes. But warnings about potential aches and pains in our muscles has put off some people from taking them. UK scientists have analysed the best statin trials and found that these side effects are actually rare – and the benefits outweigh the risks. We hear from Professor Colin Baigent in Oxford about how this study should reassure those who need to take them. On Health Check we like to bring you the best possible evidence – and for that we r...2022-08-3126 min
Masonic MuscleEp. 55 - 10 Theories on the Origins of Freemasonry. Which one is True?10 Theories on the Origins of Freemasonry
I finally read the name of a book I mentioned in a previous episode by Peary Rader, the original editor of IronMan Magazine from the early 1940’s.
The name of the book was called “The Rader Master Bodybuilding and Weight Gaining System” which was originally published in 1946
I then read a lecture that was delivered to the Quatuor Coronati Lodge No. 2076 9 November 2000
by Bro. Roeinton B. Khambatta
Inaugural Paper delivered to Quatuor Coronati Lodge No. 2076 9 November 2000
The paper was to summarize (my sum...2022-05-0531 min
Listen to The LancetThe Lancet: May 31, 2013Colin Baigent discusses the vascular and gastric effects of long-term use of high-dose non-steroidal anti-inflammatory drugs.2013-05-3111 minListen to The LancetThe Lancet: May 31, 2013Colin Baigent discusses the vascular and gastric effects of long-term use of high-dose non-steroidal anti-inflammatory drugs.2013-05-3111 minListen to The LancetThe Lancet: May 31, 2013Colin Baigent discusses the vascular and gastric effects of long-term use of high-dose non-steroidal anti-inflammatory drugs.2013-05-3111 min
The Lancet in conversation withThe Lancet: May 31, 2013Colin Baigent discusses the vascular and gastric effects of long-term use of high-dose non-steroidal anti-inflammatory drugs.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv2013-05-3111 min
Translational MedicineWider Statin Use Saves LivesColin Baigent, Professor of Epidemiology, Clinical Trial Service Unit, Oxford, talks about why the drug Statin saves lives.2012-06-1805 minTranslational MedicineWider Statin Use Saves LivesColin Baigent, Professor of Epidemiology, Clinical Trial Service Unit, Oxford, talks about why the drug Statin saves lives.2012-06-1805 minTranslational MedicineWider Statin Use Saves LivesColin Baigent, Professor of Epidemiology, Clinical Trial Service Unit, Oxford, talks about why the drug Statin saves lives.2012-06-1800 min
Green Templeton CollegeLowering Cholesterol Significantly: Archie Cochrane Lecture 2011Colin Baigent leads the CTSU's Vascular Overviews Group, which recently reported a meta-analysis of the findings among 170,000 participants in 26 randomised trials of cholesterol-lowering drugs in The Lancet.2011-05-2459 minThe Lancet in conversation withThe Lancet: May 29, 2009Colin Baigent discusses the use of aspirin for primary prevention of vascular disease.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv2009-05-2915 minListen to The LancetThe Lancet: May 29, 2009Colin Baigent discusses the use of aspirin for primary prevention of vascular disease.2009-05-2915 minListen to The LancetThe Lancet: May 29, 2009Colin Baigent discusses the use of aspirin for primary prevention of vascular disease.2009-05-2915 minListen to The LancetThe Lancet: May 29, 2009Colin Baigent discusses the use of aspirin for primary prevention of vascular disease.2009-05-2915 minThe Lancet in conversation withThe Lancet: January 14, 2008At least 170 million people worldwide are estimated to have diabetes mellitus, and this number is predicted to more than double by 2030. In this week's podcast Professor Colin Baigent from the Cholesterol Treatment Triallists Collaboration at the University of Oxford, UK, discusses a large meta-analysis which shows how people with diabetes can reduce their risk of cardiovascular events from statin therapy in the same way as people without diabetes, regardless of existing cardiovascular disease. He comments that in light of these results, all people with diabetes should be considered for statin treatment.Continue this conversation on social!...2008-01-1410 minListen to The LancetThe Lancet: January 14, 2008At least 170 million people worldwide are estimated to have diabetes mellitus, and this number is predicted to more than double by 2030. In this week's podcast Professor Colin Baigent from the Cholesterol Treatment Triallists Collaboration at the University of Oxford, UK, discusses a large meta-analysis which shows how people with diabetes can reduce their risk of cardiovascular events from statin therapy in the same way as people without diabetes, regardless of existing cardiovascular disease. He comments that in light of these results, all people with diabetes should be considered for statin treatment.2008-01-1410 minListen to The LancetThe Lancet: January 14, 2008At least 170 million people worldwide are estimated to have diabetes mellitus, and this number is predicted to more than double by 2030. In this week's podcast Professor Colin Baigent from the Cholesterol Treatment Triallists Collaboration at the University of Oxford, UK, discusses a large meta-analysis which shows how people with diabetes can reduce their risk of cardiovascular events from statin therapy in the same way as people without diabetes, regardless of existing cardiovascular disease. He comments that in light of these results, all people with diabetes should be considered for statin treatment.2008-01-1410 minListen to The LancetThe Lancet: January 14, 2008At least 170 million people worldwide are estimated to have diabetes mellitus, and this number is predicted to more than double by 2030. In this week's podcast Professor Colin Baigent from the Cholesterol Treatment Triallists Collaboration at the University of Oxford, UK, discusses a large meta-analysis which shows how people with diabetes can reduce their risk of cardiovascular events from statin therapy in the same way as people without diabetes, regardless of existing cardiovascular disease. He comments that in light of these results, all people with diabetes should be considered for statin treatment.2008-01-1410 min
Audio Medica News - Medical News InterviewsMEDICINE: Meta-Analysis Proves Statins Help Patients With DiabetesAudio Journal of Medicine, January 11th, 2008
Meta-Analysis Proves Statins Help Patients With Diabetes
COLIN BAIGENT, Oxford University
REFERENCE: Lancet 371:117 January 11, 2008
Statins were foiund to cut cardiovascular event rates by a fifth among patients with both Type I and Type II diabetes in a meta-analysis of 18 000 patients from Oxford University in England and the University of Sydney in Australia. Peter Goodwin asked the lead UK investigator, Colin Baigent, about the findings and their implications.2008-01-1104 min